The global metered dose inhalers (MDIs) market is projected to experience steady growth, driven by the introduction of advanced products and the growing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. The market, which was valued at US$ 25,208.9 million in 2022, is expected to reach US$ 26,322.9 million in 2023. According to a report by Future Market Insights (FMI), the market is forecasted to expand at a compound annual growth rate (CAGR) of 4.5% between 2023 and 2033, ultimately reaching a valuation of US$ 40,895.5 million by 2033.
MDIs are widely regarded as the most common and effective treatment option for respiratory diseases, offering patients a portable, easy-to-use solution for drug delivery. Innovations such as breath-actuated metered dose inhalers have improved drug delivery and patient compliance, presenting new opportunities for manufacturers. These advanced inhalers ensure more efficient drug usage, enabling better disease management and reducing the likelihood of dosage errors.
The introduction of advanced MDI devices is further fueled by heightened regulatory scrutiny and growing consumer demand for safe, effective, and eco-friendly options. However, the rise in regulatory compliance and the costs associated with meeting environmental standards may pose challenges for manufacturers. Despite these hurdles, industry players are focusing on R&D and the development of patient-friendly products to maintain their competitive edge.
Get the Comprehensive Full Report Now – https://www.futuremarketinsights.com/reports/metered-dose-inhalers-market
Key Takeaways:
- The global metered dose inhalers market is projected to reach US$ 40,895.5 million by 2033, up from US$ 26,322.9 million in 2023, growing at a CAGR of 4.5% during the forecast period.
- Increasing prevalence of asthma, COPD, and other respiratory diseases is a key driver of demand for MDIs.
- Advances in MDI technology, including the development of breath-actuated inhalers, are improving patient compliance and drug efficiency.
- Companies are investing in R&D to launch next-generation MDIs that address regulatory challenges and offer enhanced drug delivery performance.
- While regulatory compliance is a challenge for manufacturers, the demand for eco-friendly inhalers presents a growth opportunity in the market.
With the rising burden of respiratory diseases worldwide, the metered dose inhalers market is set to witness significant growth. Manufacturers are focusing on developing products that not only meet regulatory requirements but also enhance patient adherence. The introduction of new, advanced MDI devices and increased investment in R&D are expected to sustain the market’s steady growth trajectory over the coming decade.
Key Market Drivers
- Introduction of Advanced Products: The development of new and advanced inhaler technologies, such as breath-actuated metered dose inhalers, is enhancing patient compliance and ease of use, which is driving market growth.
- Rising Incidence of Respiratory Diseases: The increasing prevalence of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD) is significantly boosting the demand for metered dose inhalers as they provide effective delivery of medication directly to the lungs.
- Regulatory Support and Approvals: The growing number of regulatory approvals for innovative inhaler products is facilitating market expansion, allowing manufacturers to introduce enhanced devices that meet patient needs.
- Increased Awareness and Education: Rising awareness about respiratory diseases and the importance of effective treatment options among both healthcare professionals and patients is contributing to higher adoption rates of MDIs.
- Technological Advancements: Continuous improvements in inhaler technology, such as the use of hydrofluoroalkane (HFA) propellants and other innovations, are making MDIs more effective and user-friendly.
Competitive Landscape
Some of the prominent players working in the global market are:
- Cipla Inc.
- Presspart Manufacturing Ltd.
- Midascare Pharmaceuticals Pvt. Ltd.
- Beximco Pharma Ltd.
- GlaxoSmithKline Pharmaceuticals Ltd.
- 3M Pharmaceuticals Pty Ltd.
- Biocare Manufacturing Sdn Bhd.
- Anomatic Innovation & Design Center & Manufacturing
- Aristo Pharma Ltd.
- Intech Biopharm Corporation
- Swiss Pharmaceuticals Pvt. Ltd.
Some of the Important Developments of the Key Players in the Market
- In 2018, Novartis launched Symbicort. This inhaler is used to control and prevent the symptoms of asthma in adults and children at least 6 years old and is also used to control the symptoms of chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema
- In 2019, Propeller Health launched Diskus®. This product is used to control and prevent symptoms like wheezing and shortness of breath caused by asthma and ongoing lung diseases such as chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema.
- In January 2023, Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as Cipla) announced the launch of Cippoint, a point-of-care testing device where this state-of-the-art device might offer a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is CE IVD approved – indicating the device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions.
Key Companies Profiled
- Cipla Inc.
- Presspart Manufacturing Ltd.
- Midascare Pharmaceuticals Pvt. Ltd.
- Beximco Pharma Ltd.
- GlaxoSmithKline Pharmaceuticals Ltd.
- 3M Pharmaceuticals Pty Ltd.
- Biocare Manufacturing Sdn Bhd.
- Anomatic Innovation & Design Center & Manufacturing
- Aristo Pharma Ltd.
- Intech Biopharm Corporation
- Swiss Pharmaceuticals Pvt. Ltd.
Key Segments of the Metered Dose Inhalers Market
By Type:
- Preventive Inhale
- Reliever Inhaler
- Long-Acting Bronchodilators Inhaler
By End-User:
- Homecare
- Hospitals
- Clinics
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- The Middle East and Africa
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Cryoballoon Ablation System Market
Ligament Augmentation Market
Cardiac Rhythm Remote Monitoring Devices Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube